# Daratumumab in HLA Desensitization Prior to Transplantation

> **NCT05300451** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Barry A. Boilson** · enrollment: 10 (estimated)

## Conditions studied

- Cardiac Transplant

## Interventions

- **BIOLOGICAL:** Daratumumab and hyaluronidase-fihj

## Key facts

- **NCT ID:** NCT05300451
- **Lead sponsor:** Barry A. Boilson
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-03-31
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05300451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05300451, "Daratumumab in HLA Desensitization Prior to Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05300451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*